Travere plans to lay off 20% of workforce as it focuses on full approval for kidney disease drug
Travere Therapeutics is laying off about 20% of its employees in order to extend its cash runway into 2028 with a mission to convert Filspari …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
